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Summary
. In 2016, the median height z-score for prevalent
paediatric patients on dialysis was −1.8 and −1.1
for those with a functioning transplant (p ,
0.0001).
. The median weight z-score for children receiving
dialysis in 2016 was −1.2 compared with −0.2 for
children with a functioning transplant.
. The median systolic blood pressure (SBP) z-score
for transplanted children was 0.3 compared with
0.9 for dialysis patients (p , 0.0001).
. Of those with complete data, 72% of the prevalent
paediatric renal replacement therapy (RRT) popula-
tion in 2016 had one or more risk factors for cardio-
vascular disease; 6% had three risk factors present.
. All centres reported quarterly laboratory data in
2016. Quarterly data for transplant patients revealed
a median creatinine of 77 mmol/L. Data for dialysis
patients revealed median values within the normal
range for most biochemical and laboratory param-
eters, however wide inter-centre variation was seen
for parameters such as ferritin and phosphate.
Evidence of hyperparathyroidism (median parathy-
roid hormone (PTH) 16.5 pmol/L) was noted within
this cohort.
. Most (91%) prevalent transplant patients achieved
the national haemoglobin standard in 2016: 86%
had a normal range bicarbonate level and 81% had
a PTH within acceptable range.
. For prevalent patients on haemodialysis in 2016,
56% achieved SBP values of less than the 90th
percentile. Achievement of standards was 71%,
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79%, 54% and 41% for haemoglobin, calcium, phos-
phate and PTH respectively.
. For prevalent patients on peritoneal dialysis in 2016,
65% achieved SBP values of less than the 90th per-
centile. Achievement of standards was 77%, 69%,
59% and 35% for haemoglobin, calcium, phosphate
and PTH standards respectively.
Introduction
This chapter focuses on the following variables for the
prevalent paediatric dialysis and transplantation cohort
on 31 December 2016:
1. The completeness of data returns to the UK Renal
Registry (UKRR)
2. Anthropometric characteristics and growth
3. Cardiovascular risk factors (CVRFs)
4. Laboratory, clinical and biochemical indices
relevant to the management of established renal
failure.
Analyses are reported for prevalent patients aged
,18 years managed in paediatric centres receiving
chronic RRT for the year 2016 and for the time period
2002–2016 (inclusive).
Methods
Processes for data collection for the paediatric UKRR are
described in chapter 4. The data presented in this chapter relate
to the annual census date of 31 December 2016.
Standards and standardisation
Standards are in bold text and are from the Renal Association’s
(2002) Treatment of adults and children with renal failure:
standards and audit measures (third edition) [1], unless otherwise
stated.
Data for height, weight, body mass index (BMI) and SBP vary
with age, sex and size and are therefore presented as z-scores.
Anthropometry
‘Measures of supine length or standing height and weight
should be monitored at each clinic visit. All measurements
should be plotted on European reference growth charts for
healthy children.’
The reference range for height, weight and body mass index
in childhood varies with gender and age. BMI was calculated
using the formula BMI = weight (kg)/height2 (m). Height
and weight were adjusted for age. To account for discrepancies
in linear growth secondary to renal disease, BMI was expressed
according to height-age, rather than chronological age. The
International Obesity Taskforce deﬁnition [2] was used to
deﬁne overweight and obesity; z-scores were calculated based
on the British 1990 reference data for height and weight [3].
Blood pressure
‘Blood pressure varies throughout childhood and should be
maintained within two standard deviations of the mean for
normal children of the same height and sex. The systolic
blood pressure during peritoneal dialysis or after haemodialy-
sis should be maintained at <90th centile for age, gender and
height.’
‘In paediatric renal transplant patients, the systolic blood
pressure should be maintained at <90th percentile for age,
gender and height.’
The analyses of systolic blood pressure in this report
describe the achievement of values at or below the 90th percen-
tile. Guidance for blood pressure in paediatric renal transplant
patients was based on 2011 British Association for Paediatric
Nephrology recommendations [4].
The reference range for SBP varies with gender, age and
height. The data are therefore presented as z-scores based on
data from the fourth report of the National High Blood
Pressure Education Programme working group in the United
States [5].
Cholesterol
The National Heart Lung and Blood Institute recommends
screening children at risk of secondary dyslipidaemias includ-
ing those with chronic kidney disease (CKD) [6]. Given the
potential long-term cardiovascular beneﬁt and minimal harm
associated with testing, this recommendation was endorsed
by the Kidney Disease Improving Global Outcomes (KDIGO)
working group. Their 2013 clinical guidance on lipid manage-
ment recommends annual measurement of fasting lipid levels
in children with CKD, including those on RRT [7]. Both organ-
isations consider a high total cholesterol as55.2 mmol/L [6].
This cut-off has been adopted for this report.
Haemoglobin and Ferritin
The National Institute for Health and Care Excellence
(NICE) guidance on the management of anaemia in adults
and children with CKD was updated in 2015 and was used to
describe haemoglobin (Hb) ﬁndings for this report [8].
‘Typically maintain the aspirational Hb range between
100 and 120 g/L for young people and children aged 2 years
and older, and between 95 and 115 g/L for children younger
than 2 years of age, reﬂecting the lower normal range in
that age group.’
New recommendations suggest that ferritin alone is insufﬁ-
cient for assessment of iron deﬁciency status. Isolated serum
ferritin however may be used to guide maximum iron levels.
‘Do not request transferrin saturation or serum ferritin
measurement alone to assess iron deﬁciency status in people
with anaemia of CKD.’
‘In people treated with iron, serum ferritin levels should
not rise above 800 micrograms/litre. In order to prevent
this, review the dose of iron when serum ferritin levels reach
500 micrograms/litre.’
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In view of this, the reporting of ferritin in relation to the
recognition of anaemia has been removed from this year’s
report. Quarterly ferritin data by centre is reported; this should
only be interpreted in the context of maximum iron levels.
Hb and ferritin were analysed using age-related laboratory
reference ranges as in table 11.1.
Calcium, phosphate and parathyroid hormone
‘Serum phosphate and calcium should be kept within the
normal range. PTH levels should be maintained within
twice the upper limit of the normal range but, contrary to
adult standards, may be kept within the normal range if
growth is normal.’
Calcium, phosphate and PTH were analysed using age-
related laboratory reference ranges as in table 11.1. Individual
variable data analysis has been performed by centre and nation-
ally. It should be noted that ‘normal’ growth is difﬁcult to deter-
mine in relation to paediatric established renal failure (ERF).
Bicarbonate
‘Serum bicarbonate concentrations should be between 20
and 26 mmol/L.’
Bicarbonate reference ranges varied by centre and are
reported as within or outside the reference range as given in
table 11.1.
Cardiovascular risk factors (CVRFs)
A cross-sectional assessment of the prevalence of risk factors
for cardiovascular disease in paediatric patients with ERF was
performed. Risk factors described include hypertension, over-
weight/obesity and hypercholesterolaemia. Evidence pertaining
to childhood CVRFs and their association with long-term cardio-
vascular risk is available from The National Heart Lung and Blood
Institute [6].
Statistical analyses
Annual and quarterly clinical and laboratory data have been
analysed separately, with annual data being used unless stated
otherwise. Data were analysed to calculate summary statistics
(maximum, minimum, mean and median values in addition to
standard deviation and interquartile ranges). Where applicable,
the percentage achieving the audit standard was also calculated.
If a patient had missing data, they were excluded from the relevant
analyses. Centre-speciﬁc data for each UK paediatric nephrology
centre is presented where completeness reaches at least 50%.
Estimated glomerular ﬁltration rate (eGFR) was calculated
using the updated ‘bedside’ Schwartz formula [9], using centre-
speciﬁc individual correction factors submitted to the UKRR.
Caution should be taken when interpreting results based on a
single annual measurement per patient. Furthermore, additional
factors that may impact the analysis include the assays used by
centres and timing of blood results in relation to RRT. All analyses
were performed using SAS 9.3.
Results
Data completeness
Annual data
Tables 11.2 and 11.3 show the completeness of annual
data returns for transplant and dialysis prevalent patients
in 2016.
Data returns for 2016 were lower than previous years for
key variables such as height, weight and systolic blood
pressure in both transplant and dialysis patients. As in
previous years, transplant patients tended to have better
data completeness for these variables, although this too
has fallen. Haematological and biochemical parameters
collected (including haemoglobin, creatinine, bicarbonate
and PTH) had.90% completeness overall for both groups
of patients. In 2016, completeness of erythropoietin stimu-
lating agent (ESA) and IV iron use was extremely poor,
with many sites not submitting any data. Analyses includ-
ing these variables have therefore been removed from this
year’s report. Growth hormone use (data not shown) had
18% completeness and was also omitted from analyses.
Table 11.1. Summary of relevant biochemical clinical audit measures
Parameter
Age (years)
,1 1–5 6–12 .12
Hb (g/L) Maintain 95–115 if
aged ,2 years
Maintain 100–120 if
aged .2 years
100–120 100–120
Ferritin (mg/L) 200–500 200–500 200–500 200–500
Corrected calcium (mmol/L) 2.24–2.74 2.19–2.69 2.19–2.69 2.15–2.55
Phosphate (mmol/L) 1.10–1.95 1.05–1.75 1.05–1.75 1.05–1.75
PTH (individual centre) Within twice the normal range
Levels may be maintained within normal range if growing appropriately
Bicarbonate (mmol/L) Reported as either within or outside centre reference range
Hb – haemoglobin; PTH – parathyroid hormone
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Quarterly data
All thirteen centres supplied quarterly 2016 data to the
UKRR. Completeness of these data is shown for trans-
plant patients in table 11.4 and dialysis patients in
table 11.5. PTH and ferritin were not used widely in
transplant patients and therefore have been omitted
from the table.
Growth
Height
Figures 11.1 and 11.2 demonstrate that children
receiving RRT were shorter for their age and gender
than the general childhood population; this was par-
ticularly pronounced for children on dialysis. The trans-
plant median height z-score (shown by the dotted line)
Table 11.2. Percentage data completeness for transplant patients ,18 years old by centre for each variable and total number of
patients per centre on 31/12/2016, (annual data return)
Transplant patients
Centre N Height Weight BMI SBP Hb Creat Ferr ESA IV iron Chol Bicarb PTH Ca Phos
Bham_P 89 82.0 82.0 82.0 84.3 93.3 97.8 49.4 0.0 0.0 65.2 96.6 93.3 97.8 97.8
Blfst_P 22 95.5 100.0 95.5 95.5 90.9 90.9 81.8 90.9 90.9 86.4 90.9 86.4 90.9 90.9
Brstl_P 40 95.0 97.5 92.5 97.5 100.0 100.0 67.5 100.0 100.0 60.0 97.5 77.5 100.0 100.0
Cardf_P 26 88.5 92.3 84.6 92.3 96.2 96.2 88.5 7.7 7.7 84.6 96.2 88.5 96.2 96.2
Glasg_P 43 100.0 100.0 100.0 100.0 86.1 86.1 62.8 100.0 100.0 44.2 86.1 83.7 86.1 86.1
L Eve_P 80 98.8 98.8 98.8 97.5 98.8 98.8 73.8 0.0 0.0 87.5 98.8 98.8 98.8 98.8
L GOSH_P 147 98.0 97.3 93.9 99.3 96.6 96.6 81.6 0.0 0.0 66.7 96.6 94.6 96.6 96.6
Leeds_P 69 89.9 95.7 89.9 95.7 98.6 98.6 87.0 98.6 98.6 53.6 98.6 91.3 98.6 97.1
Livpl_P 46 95.7 95.7 95.7 95.7 100.0 100.0 97.8 0.0 0.0 80.4 100.0 93.5 100.0 100.0
Manch_P 63 0.0 0.0 0.0 98.4 98.4 98.4 68.3 0.0 0.0 71.4 98.4 96.8 98.4 98.4
Newc_P 27 96.3 96.3 96.3 96.3 100.0 100.0 77.8 0.0 0.0 66.7 100.0 85.2 100.0 100.0
Nottm_P 77 93.5 100.0 93.5 89.6 100.0 100.0 87.0 98.7 98.7 87.0 100.0 83.1 98.7 98.7
Soton_P 26 92.3 96.2 92.3 88.5 92.3 96.2 92.3 96.2 96.2 76.9 92.3 92.3 92.3 92.3
UK 755 86.0 87.6 84.9 94.8 96.7 97.4 76.6 36.3 36.3 70.7 97.0 91.1 97.1 97.0
BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Creat – creatinine; Ferr – ferritin; ESA – erythropoietin stimulat-
ing agent; IV – intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca – calcium; Phos – phosphate
Table 11.3. Percentage data completeness for dialysis patients ,18 years old by centre for each variable and total number of
patients per centre on 31/12/2016, (annual data return)
Centre
Dialysis patients
N Height Weight BMI SBP Hb Ferr ESA IV iron Chol Bicarb PTH Ca Phos
Bham_P 23 87.0 91.3 87.0 95.7 95.7 91.3 0.0 0.0 91.3 95.7 95.7 95.7 95.7
Blfst_P 8 100.0 100.0 100.0 100.0 87.5 87.5 87.5 87.5 87.5 87.5 87.5 87.5 87.5
Brstl_P 15 100.0 100.0 100.0 100.0 100.0 100.0 100.0 93.3 73.3 100.0 100.0 100.0 100.0
Cardf_P 9 88.9 100.0 88.9 88.9 100.0 100.0 0.0 0.0 66.7 100.0 100.0 100.0 100.0
Glasg_P 17 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 58.8 100.0 100.0 100.0 100.0
L Eve_P 28 64.3 78.6 60.7 57.1 92.9 89.3 0.0 0.0 14.3 89.3 92.9 92.9 92.9
L GOSH_P 37 83.8 89.2 81.1 91.9 100.0 78.4 0.0 0.0 48.7 100.0 100.0 100.0 100.0
Leeds_P 12 75.0 100.0 75.0 100.0 100.0 91.7 100.0 100.0 83.3 100.0 100.0 91.7 100.0
Livpl_P 9 88.9 88.9 88.9 88.9 88.9 88.9 0.0 0.0 33.3 88.9 88.9 88.9 88.9
Manch_P 25 0.0 0.0 0.0 100.0 100.0 100.0 0.0 0.0 64.0 100.0 100.0 100.0 100.0
Newc_P 5 100.0 100.0 100.0 100.0 100.0 100.0 0.0 0.0 40.0 100.0 80.0 100.0 100.0
Nottm_P 17 52.9 82.4 52.9 58.8 100.0 94.1 100.0 100.0 64.7 100.0 94.1 100.0 100.0
Soton_P 4 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 50.0 100.0 100.0 100.0 100.0
UK 209 72.7 80.4 71.8 88.0 97.6 91.9 34.5 34.0 57.9 97.1 96.7 97.1 97.6
BMI – body mass index; SBP – systolic blood pressure; Hb – haemoglobin; Ferr – ferritin; ESA – erythropoietin stimulating agent;
IV – intravenous; Chol – cholesterol; Bicarb – bicarbonate; PTH – parathyroid hormone; Ca – calcium; Phos – phosphate
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Table 11.4. Percentage data completeness for transplant patients ,18 years old by centre reporting quarterly laboratory data and
total number of patients per centre on 31/12/2016
Transplant patients
Centre N patients Creatinine Hb Calcium Phosphate Bicarbonate
Bham_P 89 90.2 55.2 90.2 90.2 89.6
Blfst_P 22 89.9 87.3 89.9 89.9 89.9
Brstl_P 40 94.0 90.6 87.9 87.9 85.9
Cardf_P 26 94.8 93.8 93.8 92.7 90.6
Glasg_P 43 82.8 82.8 82.8 82.8 82.8
L Eve_P 80 98.1 97.1 98.1 98.1 98.1
L GOSH_P 147 94.5 93.7 94.3 93.7 93.0
Leeds_P 69 95.7 95.7 93.3 93.3 95.3
Livpl_P 46 100.0 98.9 100.0 100.0 100.0
Manch_P 63 98.7 99.2 98.7 98.3 98.7
Newc_P 27 95.5 92.1 95.5 95.5 94.4
Nottm_P 77 90.2 86.7 86.4 86.0 86.4
Soton_P 26 94.6 76.3 80.6 78.5 80.6
UK 755 94.0 88.3 92.5 92.2 92.1
Hb – haemoglobin
Table 11.5. Percentage data completeness for dialysis patients ,18 years old by centre reporting quarterly laboratory data and total
number of patients per centre on 31/12/2016
Dialysis patients
Centre N patients Hb Ferritin Calcium Phosphate PTH Bicarbonate
Bham_P 23 69.8 75.0 92.7 92.7 88.5 92.7
Blfst_P 8 87.9 87.9 87.9 87.9 81.8 87.9
Brstl_P 15 89.2 78.5 89.2 89.2 87.7 89.2
Cardf_P 9 100.0 97.3 100.0 100.0 97.3 100.0
Glasg_P 17 95.1 88.5 91.8 91.8 91.8 95.1
L Eve_P 28 88.3 87.2 90.4 90.4 90.4 89.4
L GOSH_P 37 98.5 59.4 98.5 98.5 97.7 98.5
Leeds_P 12 100.0 91.8 98.0 100.0 98.0 100.0
Livpl_P 9 100.0 100.0 100.0 100.0 23.7 100.0
Manch_P 25 100.0 100.0 100.0 100.0 100.0 100.0
Newc_P 5 100.0 89.7 100.0 100.0 96.6 100.0
Nottm_P 17 98.4 93.5 98.4 98.4 93.5 98.4
Soton_P 4 95.7 95.7 100.0 100.0 100.0 100.0
UK 209 93.2 84.5 95.7 95.9 90.6 96.1
Hb – haemoglobin; PTH – parathyroid hormone
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was −1.1 and the dialysis median z-score was −1.8
(p, 0.0001). Manchester was excluded from both
analyses as no 2016 data were submitted to the UKRR
for analysis. Examining height z-score at start of RRT
(ﬁgure 11.3) suggests that children of all age groups
were short for their age and height, with an overall
median height z-score of −1.5. As in previous years,
younger children, particularly two to less than four year
olds, appeared worse off compared with older age-
groups.
Weight
Figure 11.4 shows that paediatric patients with a func-
tioning transplant had a relatively normal weight z-score
for age and gender despite a shorter height: overall
median z-score was −0.2. Dialysis patients however had
a lower weight for age and gender with a median z-
score of−1.2 (ﬁgure 11.5), although small numbers ham-
per further inter-centre analysis. This difference in weight
was signiﬁcant when compared between modality groups
(p , 0.0001).
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Cardiovascular risk factor evaluation
Obesity
Examination of BMI by height-age and gender
revealed that children in 2016 with functioning trans-
plants had a signiﬁcantly higher BMI than those receiving
dialysis. The median z-score for the respective groups was
1.0 in the transplant group (ﬁgure 11.6) and 0.3 in the
dialysis group (ﬁgure 11.7; p, 0.0001): both median
scores fall within the ‘normal’ BMI category. Manchester
was excluded from this analysis given the lack of available
height data.
Analysing BMI category by modality, over half of chil-
dren with transplants (56.6%) and over three-quarters of
dialysis patients (76.7%) were classiﬁed as having a
normal BMI (ﬁgure 11.8). Small numbers of patients
within both groups were deemed underweight (,5%).
A much larger proportion of children with a functioning
transplant were found to be overweight or obese,
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compared with those on dialysis (42.2% vs 19.3% respect-
ively, p , 0.0001).
Increasing age was associated with higher rates of
overweight and obese BMI when analysed using the
Mantel-Haenszel method (p = 0.003 data not shown).
There were no signiﬁcant differences seen by sex,
ethnicity or transplant donor type when comparing
proportions of underweight/normal BMI with over-
weight or obese categories.
Hypertension
Figures 11.9 and 11.10 display median systolic blood
pressure (SBP) z-scores by centre for paediatric trans-
plant and dialysis patients respectively, compared with
the healthy population. Manchester was excluded from
both analyses due to a lack of the 2016 height data needed
for standardisation. London Evelina was excluded from
ﬁgure 11.10 as less than 50% of patients had available
data for both SBP and height variables. In 2016, trans-
plant patients had a relatively normal SBP z-score of
0.3; interquartile ranges for only two centres crossed
the 90th centile, while over half spanned zero. Compared
with transplant patients, dialysis patients had a signiﬁ-
cantly higher median SBP z-score of 0.9 (p, 0.0001),
with wide inter-centre variability seen due to the small
numbers.
When auditing achievement of SBP standard by
modality, a target blood pressure of less than the 90th
percentile was achieved in 84.3%, 65.2% and 55.6% of
patients with a functioning transplant, on peritoneal
dialysis and on haemodialysis respectively. Small
numbers precluded further analysis by strata. This
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Fig. 11.8. BMI categorisation in children ,18 years old by
modality on 31/12/2016
Centre
SB
P 
z-
sc
or
e
N
ew
c_
P
So
to
n_
P
Ca
rd
f_
P
L 
G
O
SH
_P
Li
vp
l_
P
Bh
am
_P
G
la
sg
_P
Br
st
l_
P
Bl
fs
t_
P
Le
ed
s_
P
U
K
0.0
1.0
2.0
3.0
4.0
–4.0
–3.0
–2.0
–1.0
N = 129 Upper quartile
 Median
 Lower quartile
Dotted line shows the 90th centile
Fig. 11.10. Median SBP z-scores for dialysis
patients ,18 years old on 31/12/2016, centre
speciﬁc and national averages
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Fig. 11.9. Median SBP z-scores for
transplant patients ,18 years old on
31/12/2016, centre speciﬁc and national
averages
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difference was signiﬁcant between transplant and dialysis
patients (table 11.6, p =,0.0001). Analysing SBP within
the total prevalent RRT cohort, signiﬁcant differences
were seen by age and ethnicity. Older children were
more likely to achieve the SBP standard compared with
younger children, this difference persisted (p = 0.002)
when analysing only children with a functioning trans-
plant; small dialysis numbers prohibited a comparable
analysis. Differences between ethnic groups were also
seen. White patients were more likely to achieve the
SBP standard (83.1%), whilst South Asian patients were
least likely (71.4%). No differences were seen when SBP
was analysed by dialysis modality or transplant donor
type.
Prevalence of cardiovascular risk factors
Table 11.7 demonstrates the proportion of prevalent
RRT patients with identiﬁed CVRFs: this analysis was
restricted to the 553 of 964 (57.4%) patients with data
for all three risk factors. Of those with complete data,
over a quarter of patients (27.7%) had no recorded
CVRF, 41.4% had one CVRF, with under a third of
patients (30.9%) having two or more CVRFs. The most
frequently occurring CVRF was high BMI (overweight/
obese categories), affecting 40.5% of prevalent patients.
There were no statistically signiﬁcant differences in the
number of CVRFs according to age-group, ethnicity or
modality.
Laboratory and clinical indices – quarterly data
Tables 11.8 and 11.9 display the median values and
interquartile ranges (IQRs) of quarterly laboratory data
for prevalent 2016 paediatric transplant and dialysis
patients, by centre. For transplant patients, PTH and
ferritin data completeness was poor (less than 50%
complete for six and 12 paediatric centres respectively),
and was therefore omitted from table 11.8. Overall, trans-
planted paediatric patients continued to demonstrate
good renal allograft function with associated satisfactory
biochemistry and anaemia control as a result. For dialysis
patients, overall median values for haematological para-
meters and bicarbonate were satisfactory. While overall
median values for corrected calcium and phosphate
were normal, there was evidence of hyperparathyroidism
(median PTH 16.5 pmol/L). Wide variation was noted
in median values for ferritin, phosphate and PTH by
centre.
Table 11.6. Percentage of patients ,18 years old achieving the
standard for SBP on 31/12/2016
N
% below 90th
percentile p-value
Total 733 80.1
Age group (years) 0.04
0–,5 84 70.2
5–,12 291 79.0
12–,16 237 81.9
16–,18 121 86.0
Gender 0.7
Male 462 80.5
Female 271 79.3
Ethnicity 0.04
Black 33 75.8
Other 58 77.6
South Asian 105 71.4
White 526 83.1
RRT modality ,0.0001
Dialysis 129 60.5
Transplant 604 84.3
Table 11.7. Frequency of number of CVRFs in prevalent RRT patients ,18 years on 31/12/2016
Number of CV risk factors Hypertensive OW/Obese Hypercholesterolaemic N % Total %
0 No No No 153 27.7 27.7
1 Yes No No 60 10.8
No Yes No 99 17.9 41.4
No No Yes 70 12.7
2 Yes Yes No 39 7.1
Yes No Yes 46 8.3 24.8
No Yes Yes 52 9.4
3 Yes Yes Yes 34 6.1 6.1
N 179 224 202 553
Total % 32.4 40.5 36.5
CV – cardiovascular; OW – overweight
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Table 11.10 demonstrates median eGFR rates for
prevalent paediatric transplant recipients by age group
and time since transplant. Analysis was performed on
635 of the 755 (84.1%) prevalent transplant patients
with height and creatinine data available for 2016.
Overall, satisfactory graft function is noted. Younger
children tended to have better graft function at any
time point post-transplantation compared with older
children. By one year, the youngest age group
demonstrated an improvement in function, with loss
of baseline eGFR ranging between 1.6–11.3% in older
age groups. Median eGFR at one year equates to CKD
stage 3A for the oldest children, and CKD stage 2 for
younger age groups. At ﬁve years post-transplantation,
loss of baseline eGFR ranges from 5–22.5% (no data
available for patients aged 0–5 years). Small numbers
however have prevented in-depth statistical analysis of
these trends.
Table 11.8. Median quarterly laboratory data by centre in prevalent transplant patients ,18 years old on 31/12/2016
Centre
Transplant patients
Creatinine
mmol/L
Haemoglobin
g/L
Calcium
mmol/L
Phosphate
mmol/L
Bicarbonate
mmol/L
Bham_P 71 117 2.44 1.34 25
Blfst_P 73 121 2.41 1.23 23
Brstl_P 73 124 2.42 1.24 23
Cardf_P 69 128 2.46 1.27 23
Glasg_P 86 122 2.44 1.24 22
L Eve_P 80 123 2.46 1.20 23
L GOSH_P 79 121 2.42 1.38 23
Leeds_P 94 116 2.51 1.30 26
Livpl_P 80 127 2.34 1.28 23
Manch_P 74 117 2.44 1.26 22
Newc_P 64 121 2.45 1.27 23
Nottm_P 72 122 2.42 1.25 24
Soton_P 91 124 2.50 1.30 24
UK median 77 121 2.44 1.30 23
IQR (59–104) (110–131) (2.37–2.50) (1.13–1.44) (21–25)
IQR – interquartile range
Table 11.9. Median quarterly laboratory data by centre in prevalent dialysis patients ,18 years old on 31/12/2016
Centre
Dialysis patients
Haemoglobin
g/L
Ferritin
mg/L
Calcium
mmol/L
Phosphate
mmol/L
PTH
pmol/L
Bicarbonate
mmol/L
Bham_P 111 281 2.55 1.62 10.2 27
Blfst_P 122 717 2.48 1.52 12.9 25
Brstl_P 111 360 2.57 1.30 10.4 25
Cardf_P 129 315 2.62 1.53 35.1 22
Glasg_P 115 249 2.48 1.26 18.1 23
L Eve_P 105 298 2.51 1.40 32.6 23
L GOSH_P 113 229 2.46 1.60 9.1 25
Leeds_P 105 332 2.53 2.10 36.9 24
Livpl_P 107 245 2.55 1.50 13.7 25
Manch_P 107 192 2.62 1.64 19.1 26
Newc_P 110 328 2.57 1.39 6.9 25
Nottm_P 106 276 2.47 1.66 29.6 26
Soton_P 114 163 2.50 1.50 10.7 25
UK median 111 271 2.52 1.57 16.5 25
IQR (99–123) (138–484) (2.41–2.63) (1.25–1.90) (6.5–43.4) (23–28)
PTH – parathyroid hormone; IQR – interquartile range
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Laboratory and clinical indices – annual data
Laboratory data described below are for the prevalent
RRT patients aged less than 18 years and managed in
paediatric centres in 2016. Achievement of standards
was calculated using one value per patient, the most
recent value for 2016 was used in each case. Interpret-
ation of inter-centre variation is limited when stratiﬁed
by RRT modality given the small numbers.
Haemoglobin and ferritin
The proportion of patients with a functioning renal
transplant achieving the haemoglobin standard in 2016
was 91.1%, compared with 71% of haemodialysis and
77% of peritoneal dialysis patients. The proportions of
transplant and dialysis (both modalities) patients achiev-
ing the national haemoglobin standard has been consist-
ent over the last ten years: 72–75% of dialysis patients
achieved the standard over this time compared with
92–93% of transplant patients.
Calcium
The proportion of haemodialysis patients under 18
years achieving the calcium standard was slightly higher
in 2016 at 79.3% compared to the previous year. Less
than 5% of patients were hypocalcaemic and 16% were
reportedly hypercalcaemic. Of the peritoneal dialysis
cohort, a similar proportion of patients (69.1%) achieved
the calcium standard in 2016, compared with the
previous year. No PD patients were hypocalcaemic.
Phosphate
Just over half of prevalent haemodialysis and
peritoneal dialysis patients achieved the phosphate stan-
dard in 2016: 53.8% and 58.8% respectively. Similar
proportions of each patient group were hyperphospha-
taemic (32.1% of HD; 35.1% of PD patients). No differ-
ences were seen in attainment of standard by age group.
Parathyroid hormone
Little change was noted in 2016 with regards to the
overall attainment of satisfactory PTH values compared
with the previous year. The proportion of transplant
patients aged ,18 years maintaining a PTH within an
acceptable range was 80.7%; 19.3% demonstrated evi-
dence of hyperparathyroidism. For HD patients, more
patients had hyperparathyroidism (59.1%) than accepta-
ble levels (41%). This trend was similar in PD patients:
64.6% of the cohort had documented hyperparathyroid-
ism, 35.4% achieved the standard.
Bicarbonate
In 2016, 86.2% of prevalent transplant patients, 73.6%
of haemodialysis patients and 68% of peritoneal dialysis
patients had a bicarbonate level within the agreed stan-
dard range. Peritoneal dialysis patients had the highest
proportion of patients with levels exceeding the standard
(30.9%) compared to 10.4% of HD and 4.9% of transplant
patients. Fewer patients were acidotic: the proportion was
highest in the HD group (16.0%), followed by transplant
recipients (8.9%) and PD patients (1.0%).
Discussion
This chapter offers an insight into the haematological
and biochemical management of established renal failure
for children aged less than 18 years undergoing RRT in
Table 11.10. Median estimated glomerular ﬁltration rate (eGFR) by age group and time since transplantation in prevalent trans-
plant patients ,18 years old on 31/12/2016
Time since
transplantation
Age (years)
0–,5 5–,12 12–,16 16–,18
N eGFR N eGFR N eGFR N eGFR
3 months 13 66 32 80 14 64 11 60
1 year 11 83 35 71 24 63 16 57
3 years 9 77 84 67 39 59 22 55
5 years 0 77 62 55 61 25 54
57 years 0 39 60 87 57 42 53
Overall median 33 77 267 66 219 59 116 54
IQR (51–99) (53–84) (45–74) (42–70)
IQR – interquartile range
Paediatric biochemistry Nephron 2018;139(suppl1):273–286 283
paediatric centres. Comparison of laboratory and clinical
indices in most cases are made by modality type and
centre, although small numbers limit in-depth analysis
at this level. Furthermore, discrepancies in attainment
of nationally agreed standards relevant to the manage-
ment of ERF will help to identify areas for future quality
improvement work. It is hoped that data from this report
can continue to support the paediatric nephrology com-
munity to improve clinical care and outcomes for
patients.
Quarterly data
All centres submitted quarterly data to the UKRR. This
serves to strengthen future research, with more time-
points available for analyses of growth and allograft func-
tion. Median creatinine data for paediatric transplant
patients suggests good overall allograft function, with
associated normal range values seen for haematological
and biochemistry parameters. Dialysis patients demon-
strated good control of anaemia, acidosis and calcium,
although wide variation in median phosphate and PTH
values were seen across centres. The high median PTH
value of 16.5 pmol/L suggests management of hyperpar-
athyroidism remained an ongoing challenge for this
cohort. This has improved however from 2015 data (pre-
viously 21.0 pmol/L).
Highlights from the 2016 data
Data completeness for 2016 fell, thus hampering the
ability to fully report outcomes for all data items collected
by the UKRR. Key variables including height, weight and
systolic blood pressure were of good completeness. Lack
of data was particularly problematic for ESA, IV iron
and growth hormone use, as such analyses included in
previous years have been removed from this report.
Cholesterol was of sufﬁcient completeness to be included
in the CVRF analysis. It is difﬁcult to be certain of the
reasons for reduced data completeness, but this needs
to be explored.
Growth
Height at start of RRT, as well as for prevalent children
on RRT in 2016 remained lower than that of the healthy
UK paediatric population. This was strongly associated
with RRT modality, with dialysis patients demonstrating
lower height z-scores than transplanted children.
As expected, younger children at start of RRT tended
to fare worse in terms of height z-score compared with
older children, although given the small numbers and
associated wide interquartile ranges, this was based on
the observed trend. It is interesting to note that even
young people reaching ERF at the end of adolescence
were shorter than their peers (median z-score −0.9),
although this observation does not consider duration of
kidney disease, primary renal diagnosis or associated
extra-renal comorbidity and ﬁnal height as adults was
not known.
In terms of weight, transplant patients had similar
z-scores to those seen in the healthy population. Dialysis
patients by comparison were underweight, with a median
weight z-score of −1.2. As in previous years, a relatively
short height with near-normal weight attainment meant
that a high proportion of transplanted children were in
the overweight or obese BMI range (42.1% vs 19.3%
dialysis). Given that being overweight or obese was the
most frequently reported cardiovascular risk factor
within the paediatric RRT population, further analysis
of this population is warranted to understand how this
risk can be modiﬁed and reduced.
Cardiovascular risk factor evaluation
As in previous years, many prevalent RRT patients
have one or more modiﬁable cardiovascular risk factors.
For transplanted children, high BMI appears particularly
problematic, with 42.1% of the total cohort reportedly
overweight or obese for their height-age. For children
receiving dialysis, management of hypertension was a
greater issue: only 56% of haemodialysis and 66% of
peritoneal dialysis patients achieved a systolic blood
pressure below the 90th percentile in 2016. Given that
cardiac disease remained one of the most common causes
of death for young UK adults with ERF [10], timely con-
sideration and treatment of these risk factors, together
with maximizing access to transplantation, is important
for the long-term health of this population. It would
also be of value to further investigate patient and disease
characteristics of children who have no CVRF whilst on
RRT.
Laboratory and clinical indices
Attainment of standards for laboratory measures were
similar to previous years for both transplant and dialysis
patients. The updated 2015 NICE guidance on the man-
agement of anaemia in CKD has advised that ferritin
alone should not be routinely used to assess iron
deﬁciency status. In view of this, isolated ferritin data
has not been interpreted this year in the context of
anaemia management, focusing only on assessment of
maximum iron levels. In previous years, completeness
of ferritin data has been variable by centre and therefore
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difﬁcult to interpret; this is likely to reﬂect alternative
methods of anaemia assessment being used in lieu of
ferritin. Recommendations now suggest that assessment
of anaemia and responsiveness to treatment should be
based on the percentage of hypochromic red blood cells
(%HRC), reticulocyte haemoglobin content, or transfer-
rin saturation in conjunction with ferritin. Serum ferritin
can be used to guide maximum iron levels and IV iron
therapy. Information from centres on how best to collect
haematological data relating to anaemia management for
future reports is welcomed.
Future work
The UKRR has approved the use of data for an analysis
of risk factors implicated in the rate of eGFR function
decline post-transplantation in paediatric and young
adult patients. Additionally, potential quality improve-
ment projects based on ﬁndings of previous years’ reports
have been discussed amongst BAPN members at their
2018 annual meeting. For the UKRR, suggestions on
how to improve the process of timely accurate and com-
plete data returns from paediatric centres are welcomed.
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